Cerebrovascular Accident Clinical Trial
Official title:
Abciximab (ReoPro) in Acute Ischemic Stroke: A Phase III, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
The purpose of this study is to determine the effectiveness of abciximab in the treatment of acute ischemic stroke.
Abciximab is a drug that prevents platelets from sticking together and forming a clot. There
are limited studies using abciximab in the treatment of strokes. This phase III,
multicenter, randomized, double-blind, placebo-controlled, parallel group study is designed
to assess the effectiveness and safety of abciximab for treatment of acute ischemic stroke,
in helping dissolve clots in brain arteries so that blood and oxygen can flow better and
there may be less brain damage.
Safety evaluations will be performed at specified intervals throughout the study and will
consist of laboratory tests, vital signs (such as blood pressure), physical examinations and
the occurrence and severity of adverse events as well as other study specific procedures.
Patients will receive either Abciximab: 0.25 mg/kg bolus (to a maximum of 30 mg) followed by
a 0.125 µg/kg/min infusion (to a maximum of 10 µg/min) for 12 hours or a bolus of placebo
followed by infusion for 12 hours
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05477238 -
Oxygen Consumption in Post-stroke Patients During Various Walking Activities Compared to Healthy Controls
|
N/A | |
| Completed |
NCT00046293 -
ReoPro and Retavase to Treat Acute Stroke
|
Phase 2 | |
| Completed |
NCT04584645 -
A Digital Flu Intervention for People With Cardiovascular Conditions
|
N/A | |
| Completed |
NCT01116544 -
Treatment of Chronic Stroke With AMES + EMG Biofeedback
|
N/A | |
| Withdrawn |
NCT04991038 -
Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients
|
N/A | |
| Active, not recruiting |
NCT02563886 -
Electrically Assisted Movement Therapy
|
N/A | |
| Recruiting |
NCT02446730 -
Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome
|
Phase 4 | |
| Completed |
NCT02141932 -
Pocket-size Cardiovascular Ultrasound in Stroke
|
N/A | |
| Completed |
NCT01915368 -
Determining Optimal Post-Stroke Exercise (DOSE)
|
N/A | |
| Recruiting |
NCT02557737 -
Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities
|
Phase 3 | |
| Recruiting |
NCT01769326 -
Influence of Timing on Motor Learning
|
N/A | |
| Terminated |
NCT01705353 -
The Role of HMGB-1 in Chronic Stroke
|
N/A | |
| Completed |
NCT01423201 -
Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk
|
||
| Completed |
NCT01656876 -
The Effects of Mirror Therapy on Upper Extremity in Stroke Patients
|
N/A | |
| Completed |
NCT01182818 -
Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease
|
N/A | |
| Withdrawn |
NCT00573092 -
Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs
|
N/A | |
| Completed |
NCT00542256 -
tDCS and Physical Therapy in Stroke
|
N/A | |
| Completed |
NCT00377689 -
Evaluation of an Intervention Program Targeted at Improving Balance and Functional Skills After Stroke
|
Phase 2 | |
| Recruiting |
NCT00166751 -
Sonographic Assessment of Laryngeal Elevation
|
N/A | |
| Completed |
NCT00149435 -
Cardiovascular Health Study (CHS) Events Follow-up Study
|